Total Payments
$1.5M
2024 Payments
$297,379
Companies
25
Transactions
2,052
Medicare Patients
12,336
Medicare Billing
$2.1M
Payment Breakdown by Category
Other$911,029 (61.1%)
Research$205,998 (13.8%)
Travel$186,246 (12.5%)
Consulting$152,109 (10.2%)
Food & Beverage$34,903 (2.3%)
Education$101.87 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $870,750 | 335 | 58.4% |
| Unspecified | $205,998 | 55 | 13.8% |
| Travel and Lodging | $186,246 | 836 | 12.5% |
| Consulting Fee | $152,109 | 71 | 10.2% |
| Food and Beverage | $34,903 | 740 | 2.3% |
| Honoraria | $22,600 | 7 | 1.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $17,679 | 6 | 1.2% |
| Education | $101.87 | 2 | 0.0% |
Payments by Type
General
$1.3M
1,997 transactions
Research
$205,998
55 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $836,885 | 1,179 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $488,697 | 509 | $0 (2024) |
| Axsome Therapeutics, Inc. | $87,003 | 117 | $0 (2024) |
| Avadel CNS Pharmaceuticals, LLC | $24,610 | 23 | $0 (2024) |
| Pernix Therapeutics Holdings, Inc. | $22,053 | 69 | $0 (2018) |
| Noctrix Health, Inc. | $20,400 | 7 | $0 (2024) |
| EISAI INC. | $4,763 | 16 | $0 (2022) |
| Sun Pharmaceutical Industries Inc. | $3,202 | 12 | $0 (2017) |
| VERTEX PHARMACEUTICALS INCORPORATED | $426.67 | 1 | $0 (2018) |
| Vanda Pharmaceuticals Inc. | $414.20 | 21 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $297,379 | 229 | JAZZ PHARMACEUTICALS INC. ($199,113) |
| 2023 | $308,001 | 313 | Harmony Biosciences LLC ($156,800) |
| 2022 | $189,842 | 247 | Harmony Biosciences LLC ($106,510) |
| 2021 | $196,091 | 306 | HARMONY BIOSCIENCES LLC ($101,877) |
| 2020 | $137,934 | 217 | Harmony Biosciences LLC ($83,669) |
| 2019 | $102,903 | 211 | JAZZ PHARMACEUTICALS INC. ($102,590) |
| 2018 | $141,792 | 279 | Jazz Pharmaceuticals Inc. ($129,603) |
| 2017 | $116,445 | 250 | Jazz Pharmaceuticals Inc. ($102,242) |
All Payment Transactions
2,052 individual payment records from CMS Open Payments — Page 1 of 83
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $5,465.03 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $5,000.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $4,500.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $3,492.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $2,479.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $1,500.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $500.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $330.00 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/16/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $27.50 | Research |
| Study: An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $10,058.10 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $10,058.10 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $8,711.30 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $8,711.30 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $8,160.10 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $8,160.10 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $3,927.30 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $3,927.30 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $1,342.90 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $1,146.60 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/04/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | — | Cash or cash equivalent | $1,146.60 | Research |
| Study: A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy • Category: NEUROLOGY | ||||||
| 12/03/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: NEUROLOGY | ||||||
| 12/03/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $6.87 | General |
| Category: NEUROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy | JAZZ PHARMACEUTICALS INC. | $65,350 | 11 |
| An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to XYWAV | JAZZ PHARMACEUTICALS INC. | $45,944 | 22 |
| An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | Harmony Biosciences LLC | $38,393 | 13 |
| A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | Harmony Biosciences LLC | $27,166 | 4 |
| A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia | HARMONY BIOSCIENCES LLC | $16,130 | 2 |
| A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension | HARMONY BIOSCIENCES LLC | $6,463 | 1 |
| HBS-101-CL-001 | Harmony Biosciences LLC | $5,000 | 1 |
| An Open-Label Study to Evaluate the Long-Term Safety and Effectiveness of Pitolisant in Adult Patients With Idiopathic Hypersomnia Who Completed Study HBS-101-CL-010 | HARMONY BIOSCIENCES LLC | $1,553 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 4,536 | 4,818 | $2.6M | $592,205 |
| 2022 | 12 | 2,784 | 3,749 | $2.3M | $523,247 |
| 2021 | 11 | 2,913 | 5,547 | $2.7M | $557,487 |
| 2020 | 13 | 2,103 | 5,316 | $1.9M | $436,251 |
Total Patients
12,336
Total Services
19,430
Medicare Billing
$2.1M
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2023 | 1,804 | 1,956 | $1.4M | $290,727 | 20.3% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 100 | 103 | $242,295 | $63,357 | 26.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 882 | 882 | $264,794 | $57,441 | 21.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 787 | 876 | $156,300 | $50,735 | 32.5% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 73 | 73 | $202,924 | $44,417 | 21.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 424 | 424 | $159,210 | $42,979 | 27.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 358 | 393 | $86,280 | $32,499 | 37.7% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2023 | 59 | 60 | $26,141 | $5,648 | 21.6% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2023 | 34 | 35 | $15,674 | $3,327 | 21.2% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 15 | 16 | $15,250 | $1,075 | 7.0% |
| 95800 | Sleep study including heart rate, breathing, and sleep time | Office | 2022 | 825 | 1,563 | $1.2M | $250,277 | 21.6% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 97 | 105 | $313,522 | $67,229 | 21.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 605 | 605 | $228,345 | $62,877 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 567 | 636 | $146,810 | $53,293 | 36.3% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 76 | 76 | $198,853 | $42,933 | 21.6% |
| 99091 | Collection and interpretation of physical parameters stored in computers and/or transmitted by the patient and/or caregiver to qualified health care professional, requiring 30 minutes or more, per 30 days | Office | 2022 | 174 | 277 | $67,819 | $11,175 | 16.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 145 | 145 | $43,985 | $9,392 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 143 | 151 | $31,675 | $9,128 | 28.8% |
| 95810 | Sleep study in sleep lab (6 years or older) | Facility | 2022 | 50 | 50 | $21,138 | $4,923 | 23.3% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2022 | 26 | 44 | $24,150 | $4,101 | 17.0% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Facility | 2022 | 22 | 24 | $10,535 | $2,498 | 23.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 16 | $6,310 | $2,281 | 36.2% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 26 | 43 | $7,932 | $2,067 | 26.1% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2022 | 14 | 14 | $12,800 | $1,072 | 8.4% |
| 95800 | Study of sleep patterns, including sleep time | Office | 2021 | 425 | 782 | $587,012 | $133,963 | 22.8% |
About Dr. Haramandeep Singh, MD
Dr. Haramandeep Singh, MD is a Sleep Medicine healthcare provider based in San Ramon, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1154410967.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Haramandeep Singh, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $297,379 received in 2024. These payments were reported across 2,052 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($870,750).
As a Medicare-enrolled provider, Singh has provided services to 12,336 Medicare beneficiaries, totaling 19,430 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Sleep Medicine
- Location San Ramon, CA
- Active Since 10/11/2006
- Last Updated 11/05/2025
- Taxonomy Code 2084S0012X
- Entity Type Individual
- NPI Number 1154410967
Products in Payments
- XYWAV (Drug) $358,860
- Wakix (Drug) $264,464
- Xyrem (Drug) $231,845
- WAKIX (Drug) $131,081
- SUNOSI (Drug) $129,791
- XYREM (Drug) $113,514
- Sunosi (Drug) $86,993
- LUMRYZ (Drug) $24,610
- SILENOR (Drug) $22,024
- NIDRA (Device) $20,400
- Dayvigo (Drug) $4,738
- Odomzo (Drug) $3,202
- AirFit (Device) $330.56
- INSPIRE (Device) $296.49
- HETLIOZ (Drug) $271.63
- BELSOMRA (Drug) $261.51
- Trintellix (Drug) $211.78
- AUSTEDO (Drug) $172.31
- INGREZZA (Drug) $168.29
- Hetlioz (Drug) $142.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.